INTS · Intensity Therapeutics, Inc. · Executive Compensation
$3.20
-0.05 (-1.54%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$10.61M
Shares
3.26M
Volume · Oct 26
201
Avg daily vol (3M)
26.02K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $1,355,482 |
| Joseph Talamo | Chief Financial Officer | $723,739 |
| John Wesolowski | Principal Accounting Officer and Controller | $378,452 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $2,486,169 |
| Joseph Talamo | Chief Financial Officer | $1,662,576 |
| John Wesolowski | Principal Accounting Officer and Controller | $569,129 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $1,235,740 |
| John Wesolowski | Principal Accounting Officer and Controller | $527,291 |
| Joseph Talamo | Chief Financial Officer | $456,371 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $994,571 |
| John Wesolowski | Principal Accounting Officer and Controller | $251,157 |
| Joseph Talamo | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Thomas I. H. Dubin | Class I director | Appointed | 2024-07-17 |
| Daniel Donovan | Class I director | Appointed | 2024-07-17 |
| James Ahlers | officer of the Company | Terminated | 2024-05-24 |
| Thomas I. H. Dubin | Class I director | Appointed | 2024-05-15 |
| Joseph Talamo | Chief Financial Officer | Appointed | 2023-12-12 |
Leadership
- Lewis H. Bender CEO
- Joseph Talamo CFO
- Daniel Donovan Board Member
- Emer Leahy Board Member
- Mark A. Goldberg Board Member
- Thomas I. H. Dubin Board Member